Antibiotic Prophylaxis in Hematopoietic Stem Cell Transplantation: a Randomised Controlled Trial - The ANTURA trial
Key facts
- Where
- Helsinki, FinnországSee the site
- Phase
- 4. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Finnország
- HUS-YhtymaeHelsinki, FinnországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- HUS-yhtymae
- Trial code
- EU 2025-524982-25-00
- Record updated
- 2026. szeptember 23.
- Original description
The primary objective of this study is to evaluate whether antibacterial prophylaxis with levofloxacin reduces the incidence of bloodstream infections during the neutropenic phase (up to 30 days) following allogeneic hematopoietic stem cell transplantation compared with placebo.Read full original descriptionShow less
The primary objective of this study is to evaluate whether antibacterial prophylaxis with levofloxacin reduces the incidence of bloodstream infections during the neutropenic phase (up to 30 days) following allogeneic hematopoietic stem cell transplantation compared with placebo.
Inclusion: Adults (≥18 years) scheduled to undergo allogeneic hematopoietic stem cell transplantation at Helsinki University Hospital for any accepted indication.
Exclusion: Known hypersensitivity to fluoroquinolone antibiotics; Epilepsy or other known seizure disorder; History of tendinopathy during fluoroquinolone therapy; Long-QT syndrome; Acquired prolonged QT-time, cQT>500ms; Pregnancy of breastfeeding; Other known contraindication to levofloxacin or other fluoroquinolone antibiotics.